A vaccine is the ultimate goal in the fight against the coronavirus pandemic, but its arrival is likely at least a year off, with that aggressive timeline being called a moonshot by one pharmaceutical company.
In the meantime, researchers are working to identify meaningful treatment options for patients with COVID-19, the deadly respiratory illness caused by the virus. And some early experiments and trials are encouraging.
For a much-needed dose of potential good news on the pandemic front, lets consider a handful of the many efforts underway to help COVID-19 patients.
Perhaps the best-known treatment being studied right now involves the anti-malaria drug hydroxychloroquine. President Donald Trump heralded it during a March 20 press conference. A few days later an Arizona man died after self-medicating with non-pharmaceutical chloroquine phosphate, leading the Centers for Disease Control and Prevention to warn people not to take the substance to ward off coronavirus.
Despite this tragedy, hydroxychloroquine does indeed show promise in treating COVID-19, and doctors are already trying it out on patients.
Eight coronavirus patients at a veterans home in Lebanon, Oregon, for example, have been treated with hydroxychloroquine and the antibiotic azithromycin. The oldest of the patients, 104-year-old William Lapschies, appears to have fully recovered from the illness.
I was using it to give them a fighting chance, their doctor, Rob Richardson, told The Associated Press.
The Henry Ford Health System in Michigan announced last week that it is also treating some seriously ill COVID-19 patients with hydroxychloroquine.
Early indications are that the drug reduces viral shedding, which help arrest the progression of COVID-19 in patients who are experiencing shortness of breath or who have developed pneumonia.
We are not using it in outpatients, and were not using it in patients with mild infection, Henry Ford infectious-disease specialist Dr. Marcus Zervos told reporters. We are using it, however, in patients who are sick enough to be hospitalized with pneumonia who we feel are at risk of progressing their infection.
University of Minnesota infectious-disease scientist David Bouware has begun a nationwide trial to determine if hydroxychloroquine could prevent people exposed to the coronavirus from developing COVID-19. The trial will have 1,500 participants.
Bouware says he is encouraged by the data, which indicates the drug might keep the coronavirus from entering cells, but he points out its early days.
Our goal, he said, is to find out, Does this actually work?
Preventing the progression of COVID-19 once someone is infected with the coronavirus is a key objective of medical researchers. The reason: So far, a significant percentage of the patients who have had to be put on ventilators have died.
In hopes of fewer severe cases reaching that point, researchers in Belgium have launched a clinical trial of the drug Leukine.
The study will use Leukine to treat 80 Covid-19 patients who are suffering from respiratory distress but not on ventilation. The goal is to try to prevent them from going to intensive care, Partner Therapeutics chief medical officer Dr. Debasish Roychowdhury told The Oregonian/OregonLive. Massachusetts-based Partner Therapeutics owns the rights for Leukine.
Earlier studies have shown that the drug, a yeast-derived version of GM-CSF, promotes lung repair. GM-CSF, or granulocyte macrophage colony stimulating factor, is an important protein the body makes and is critical for maintaining normal, healthy lungs, Roychowdhury pointed out.
Leukine has been around for 30 years and is currently being used to aid leukemia- and- bone-marrow-transplant patients.
The safety of the drug is very well-known, Roychowdhury said.
One of the worst-case scenarios for a COVID-19 patient is cytokine storm, when the immune system overreacts to the novel virus and floods the lungs with immune cells, causing severe inflammation. One possible way to keep those patients alive is through transfusions of plasma with COVID-19 antibodies from people who have recovered from the illness.
Five COVID-19 patients with acute respiratory distress syndrome (ARDS) at a hospital in Shenzhen, China, recently received such transfusions, a study posted to the Journal of the American Medical Association (JAMA) reported on March 27.
Though the sample size is quite small (and the critically ill patients were receiving various treatments, including antiviral medications, as part of all-out efforts to save them), the results are encouraging. All five of the patients receiving the transfusions were on ventilation when the treatment began. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the study states. A month after the transfusion, three of the five patients had been released from the hospital and the other two were in stable condition.
In another small experiment, doctors treated seven COVID-19 patients with mesenchymal stem cells, which are known for their peculiar and powerful immunoregulatory abilities. This treatment also showed promise. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation, stated a study published in the journal Aging and Disease. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment -- significantly faster than is typical for both moderate and severe cases.
Another drug being studied in the fight against COVID-19 is the anti-viral Remdesivir, which was developed for Ebola.
Remdesivir might stop the coronavirus from reproducing in the body. Northwestern Memorial Hospital infectious-disease specialist Dr. Babafemi Taiwo has called it a really special drug.
These and other treatments are in the very earliest stages of study, seeing as the novel coronavirus didnt exist in humans until late last year. It remains to be seen whether they will be effective and safe in large numbers of patients.
-- Douglas Perry
@douglasmperry
Subscribe to Oregonian/OregonLive newsletters and podcasts for the latest news and top stories.
Read more from the original source:
- Proteomic analysis of human Whartons jelly mesenchymal stem/stromal cells and human amniotic epithelial stem cells: a comparison of therapeutic... - November 20th, 2024
- Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with... - November 20th, 2024
- Mesenchymal stem cells lineage and their role in disease development - November 18th, 2024
- Mesenchymal Stem Cells - SpringerLink - November 18th, 2024
- Exosomes: The Insulin of Our Era? - University of Miami - November 18th, 2024
- Partner Perspectives: Mesenchymal Stromal Cells Could Serve as Preventive Therapy for Chronic Radiation-Induced Dry Mouth - OncLive - November 10th, 2024
- Skin-care founder Angela Caglia on the stem cell technology that created 437% sales growth: 'It's transformed the business' - Glossy - November 8th, 2024
- Substantial Overview on Mesenchymal Stem Cell Biological and Physical ... - November 8th, 2024
- Regenerative Medical Technology Group Announces the Opening of New Clinic in Dubai on November 23 - Newswire - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - StockTitan - November 8th, 2024
- Stem cell science is dominating the luxury skin-care market as human-derived ingredients become less taboo - Glossy - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - The Manila Times - November 8th, 2024
- SMART researchers develop a method to enhance effectiveness of cartilage repair therapy - MIT News - October 25th, 2024
- Biological functions of mesenchymal stem cells and clinical ... - October 24th, 2024
- Chemical-defined medium supporting the expansion of human mesenchymal ... - October 24th, 2024
- Mesenchymal Stem Cells: Time to Change the Name! - PMC - October 24th, 2024
- Insights into the molecular characteristics of embryonic cranial neural crest cells and their derived mesenchymal cell pools - Nature.com - October 20th, 2024
- Acquisition of durable insulin-producing cells from human adipose tissue-derived mesenchymal stem cells as a foundation for cell- based therapy of... - October 20th, 2024
- Sources and Clinical Applications of Mesenchymal Stem Cells - October 20th, 2024
- Effects of inorganic phosphate on stem cells isolated from human exfoliated deciduous teeth - Nature.com - October 18th, 2024
- Researchers pioneer novel method to enhance effectiveness of MSC therapy for cartilage repair - Medical Xpress - October 18th, 2024
- Healing begins with research: Promising development program on stem cells in rare diseases - Yahoo! Voices - October 15th, 2024
- Unveiling the Immunomodulatory and regenerative potential of iPSC-derived mesenchymal stromal cells and their extracellular vesicles - Nature.com - October 15th, 2024
- Manufactured stem cells could help to treat blood cancers in the future - Health Tech World - October 14th, 2024
- miR-16a-5p antagonizes FGF-2 in ligamentogenic differentiation of MSC: a new therapeutic perspective for tendon regeneration - Nature.com - October 11th, 2024
- Effects, methods and limits of the cryopreservation on mesenchymal stem ... - October 10th, 2024
- ALKBH5 regulates etoposide-induced cellular senescence and osteogenic differentiation in osteoporosis through mediating the m6A modification of VDAC3... - October 10th, 2024
- Mesenchymal stromal cells: Biology of adult mesenchymal stem cells ... - October 8th, 2024
- Clever Robotic clothing and manufactured stem cells to treat cancer among revolutionary healthcare tech projects - University of Strathclyde - October 8th, 2024
- Dr. Peisong Gao, MD, PhD - Hopkins Medicine - October 4th, 2024
- Research to Boost Bone Formation Informs Orthopaedic Treatments - October 4th, 2024
- Garza Laboratory - Johns Hopkins Medicine - October 4th, 2024
- Stem Cell Treatment Promises to Prevent Disease and Slow Aging - Newsweek - September 30th, 2024
- Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells - Journal of Translational... - September 28th, 2024
- A mathematical insight to control the disease psoriasis using mesenchymal stem cell transplantation with a biologic inhibitor - Nature.com - September 20th, 2024
- Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production -... - September 20th, 2024
- Implication of CXCR2-Src axis in the angiogenic and osteogenic effects of FP-TEB - Nature.com - September 20th, 2024
- Strategic targeting of miR-183 and -catenin to enhance BMSC stemness in age-related osteoporosis therapy - Nature.com - September 16th, 2024
- The order of green and red LEDs irradiation affects the neural differentiation of human umbilical cord matrix-derived mesenchymal cells - Nature.com - September 14th, 2024
- ENCell and Lucy Biotech Sign a Strategic Alliance and Licensing Agreement for the Next generation Mesenchymal Stem Cell Therapy (EN001) - PR Newswire - September 14th, 2024
- Japanese brand Eternam taps regenerative medicine to develop lip and skin care from umbilical cord-derived stem cell - CosmeticsDesign-Asia.com - September 10th, 2024
- Advances in Tissue Engineering and Its Future in Regenerative Medicine Compared to Traditional Reconstructive Techniques: A Comparative Analysis -... - September 8th, 2024
- Editorial: The future direction toward immunological issues of allo-and xeno-islet transplantation - Frontiers - September 8th, 2024
- Translational potential of mesenchymal stem cells in regenerative ... - September 4th, 2024
- Global microRNA profiling of bone marrow-MSC derived extracellular vesicles identifies miRNAs associated with hematopoietic dysfunction in aplastic... - August 24th, 2024
- A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders - Cureus - August 22nd, 2024
- Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart... - August 22nd, 2024
- Infinite Health Integrative Medicine Center Revolutionizes Regenerative Medicine with Advanced Mesenchymal Signaling Cell Therapy - PR Newswire - August 22nd, 2024
- Stem Cell Therapy Market to Grow at 11.2% CAGR through 2031 - EIN News - August 22nd, 2024
- Immunomodulatory properties of nave and inflammation-informed dental pulp stem cell derived extracellular vesicles - Frontiers - August 20th, 2024
- Exciting advance in stem cell therapy - McGill Newsroom - August 16th, 2024
- Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with... - August 16th, 2024
- Establishment of a stem cell administration imaging method in bleomycin-induced pulmonary fibrosis mouse models - Nature.com - August 16th, 2024
- Editorial: Bringing function to the forefront of cell therapy: how do we demonstrate potency? - Frontiers - August 12th, 2024
- Anti-aging enthusiasts are having stem cell injections in their knees at more than $16K a pop - New York Post - August 10th, 2024
- Exosomes and Equine Health - Horse Sport - August 10th, 2024
- Therapeutic application of mesenchymal stem cell-derived exosomes in skin wound healing - Frontiers - August 6th, 2024
- Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results - August 2nd, 2024
- NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results - August 2nd, 2024
- Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update - August 2nd, 2024
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - August 2nd, 2024
- T2 Biosystems to Attend Upcoming Investor Conferences - August 2nd, 2024
- Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific - August 2nd, 2024
- Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device - August 2nd, 2024
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - August 2nd, 2024
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Stem cell therapy leads to short-term disability reduction in MS - Multiple Sclerosis News Today - July 22nd, 2024
- Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17/Treg balance -... - July 22nd, 2024
- Clene to Present at the Emerging Growth Conference - July 14th, 2024
- Voting Rights and Shares Capital of the Company - July 10th, 2024
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - July 10th, 2024
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 10th, 2024
- Report on Carbios’ liquidity contract with Natixis ODDO BHF - July 10th, 2024
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 10th, 2024
- Activation of cellular antioxidative stress and migration activities by purified components from immortalized stem cells ... - Nature.com - July 5th, 2024
- These 3D model brains with cells from several people are first of their kind - Nature.com - June 30th, 2024
- Introduction to Stem Cells | STEM Cell Information - June 30th, 2024
Recent Comments